12:00 AM
 | 
Jul 20, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Luminate: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 106 patients with VMT or VMA showed that 3.2 mg intravitreal Luminate met the primary endpoint of a greater proportion of patients achieving release of VMT or VMA by day 90 vs. placebo (65% vs. 9.7%, p=0.0129). Luminate was well tolerated...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >